Fda Clears Papzimeos To Treat Adult Respiratory Papillomatosis Upi With the landmark fda approval of papzimeos and broad label, all adult rrp patients are now eligible for access to the first and only approved therapy that targets the root cause of the disease," said helen sabzevari, phd, president and ceo of precigen. In conclusion, the fda approval of papzimeos is not just a win for rrp patients—it is a catalyst for precigen's evolution into a precision medicine leader. for investors, this is a rare opportunity to back a de risked, revenue generating asset with the potential to deliver outsized returns.
About Precigen With the landmark fda approval of papzimeos and broad label, all adult rrp patients are now eligible for access to the first and only approved therapy that targets the root cause of the. With the landmark fda approval of papzimeos and broad label, all adult rrp patients are now eligible for access to the first and only approved therapy that targets the root cause of the disease. Precigen inc. (nasdaq: pgen) shares have jumped nearly 150% since the us biotechnology group secured food and drug administration approval for papzimeos, the first treatment for recurrent respiratory papillomatosis (rrp), a rare disease caused by human papillomavirus (hpv) that leads to benign growths in the respiratory tract. The approval of the first non surgical treatment for adults with rrp marks not only a scientific milestone, but an inflection point for the entire rrp community.
Precigen Announces Full Fda Approval Of Papzimeos Zopapogene Precigen inc. (nasdaq: pgen) shares have jumped nearly 150% since the us biotechnology group secured food and drug administration approval for papzimeos, the first treatment for recurrent respiratory papillomatosis (rrp), a rare disease caused by human papillomavirus (hpv) that leads to benign growths in the respiratory tract. The approval of the first non surgical treatment for adults with rrp marks not only a scientific milestone, but an inflection point for the entire rrp community. Precigen’s third quarter results spotlight the transformative launch of papzimeos—the first fda approved treatment for adults with rrp—with rapid commercial uptake, strong payer coverage, and durable clinical outcomes. Precigen has received fda approval for papzimeos, the first therapy for recurrent respiratory papillomatosis, marking a major advance in patient care. Trials started in 2021, and despite pandemic related slowdowns, the drug was ultimately approved just four years later. and although papzimeos was once on a path to accelerated approval, which would require a post market confirmatory trial, the fda instead gave it a full nod. In august 2025, precigen achieved a historic milestone with the fda’s full approval of papzimeos™ (zopapogene imadenovec drba), the first and only therapy approved for adults suffering from recurrent respiratory papillomatosis (rrp).
4 Years From Clinic To Approval Precigen S Unprecedented Fda Nod Precigen’s third quarter results spotlight the transformative launch of papzimeos—the first fda approved treatment for adults with rrp—with rapid commercial uptake, strong payer coverage, and durable clinical outcomes. Precigen has received fda approval for papzimeos, the first therapy for recurrent respiratory papillomatosis, marking a major advance in patient care. Trials started in 2021, and despite pandemic related slowdowns, the drug was ultimately approved just four years later. and although papzimeos was once on a path to accelerated approval, which would require a post market confirmatory trial, the fda instead gave it a full nod. In august 2025, precigen achieved a historic milestone with the fda’s full approval of papzimeos™ (zopapogene imadenovec drba), the first and only therapy approved for adults suffering from recurrent respiratory papillomatosis (rrp).
Precigen Announces Full Fda Approval Of Papzimeos Zopapogene Trials started in 2021, and despite pandemic related slowdowns, the drug was ultimately approved just four years later. and although papzimeos was once on a path to accelerated approval, which would require a post market confirmatory trial, the fda instead gave it a full nod. In august 2025, precigen achieved a historic milestone with the fda’s full approval of papzimeos™ (zopapogene imadenovec drba), the first and only therapy approved for adults suffering from recurrent respiratory papillomatosis (rrp).
Comments are closed.